204 related articles for article (PubMed ID: 16401468)
1. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2.
Fries S; Grosser T; Price TS; Lawson JA; Kapoor S; DeMarco S; Pletcher MT; Wiltshire T; FitzGerald GA
Gastroenterology; 2006 Jan; 130(1):55-64. PubMed ID: 16401468
[TBL] [Abstract][Full Text] [Related]
2. More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib.
Hinz B; Dormann H; Brune K
Arthritis Rheum; 2006 Jan; 54(1):282-91. PubMed ID: 16385545
[TBL] [Abstract][Full Text] [Related]
3. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
Baron JA; Sandler RS; Bresalier RS; Quan H; Riddell R; Lanas A; Bolognese JA; Oxenius B; Horgan K; Loftus S; Morton DG;
Gastroenterology; 2006 Dec; 131(6):1674-82. PubMed ID: 17087947
[TBL] [Abstract][Full Text] [Related]
5. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Spalding WM; Reeves MJ; Whelton A
Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
[TBL] [Abstract][Full Text] [Related]
6. Can the blood pressure effects of COX-2 selective inhibitors be explained by changes in plasma aldosterone levels?
Aw TJ; Liew D; Tofler GH; Schneider HG; Morel-Kopp MC; Billah B; Krum H
J Hypertens; 2006 Oct; 24(10):1979-84. PubMed ID: 16957557
[TBL] [Abstract][Full Text] [Related]
7. Effects of selective cyclooxygenase isoform inhibition on systemic prostacyclin synthesis and on platelet function at rest and after exercise in healthy volunteers.
Weber AA; Heim HK; Schumacher M; Schrör K; Hohlfeld T
Platelets; 2007 Aug; 18(5):379-85. PubMed ID: 17654308
[TBL] [Abstract][Full Text] [Related]
8. Rofecoxib 50 mg and valdecoxib 20 or 40 mg in adults and adolescents with postoperative pain after third molar extraction: results of two randomized, double-blind, placebo-controlled, single-dose studies.
Daniels SE; Desjardins PJ; Bird SR; Smugar SS; Tershakovec AM
Clin Ther; 2006 Jul; 28(7):1022-34. PubMed ID: 16990080
[TBL] [Abstract][Full Text] [Related]
9. COX-2 selective inhibitors and heart health.
Simon LS; White WB
Postgrad Med; 2005 Jan; 117(1 Suppl):7-20. PubMed ID: 19667717
[TBL] [Abstract][Full Text] [Related]
10. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
[TBL] [Abstract][Full Text] [Related]
11. COX-2 inhibitors and heart.
Manoria P; Manoria PC
Indian Heart J; 2005; 57(6):772-7. PubMed ID: 16521658
[No Abstract] [Full Text] [Related]
12. [Use of rofecoxib in family practice in the north of Netherlands, 2000-2004: background and consequences].
van der Veen WJ; van der Werf GT
Ned Tijdschr Geneeskd; 2006 May; 150(18):1016-21. PubMed ID: 16715866
[TBL] [Abstract][Full Text] [Related]
13. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial.
Lanas A; Baron JA; Sandler RS; Horgan K; Bolognese J; Oxenius B; Quan H; Watson D; Cook TJ; Schoen R; Burke C; Loftus S; Niv Y; Ridell R; Morton D; Bresalier R
Gastroenterology; 2007 Feb; 132(2):490-7. PubMed ID: 17258718
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of rofecoxib 50 mg and hydrocodone/acetaminophen 7.5/750 mg in patients with post-arthroscopic pain.
Chelly JE; Nissen CW; Rodgers AJ; Smugar SS; Tershakovec AM
Curr Med Res Opin; 2007 Jan; 23(1):195-206. PubMed ID: 17207303
[TBL] [Abstract][Full Text] [Related]
15. COX-2 inhibitors and cardiovascular risk.
Funk CD; FitzGerald GA
J Cardiovasc Pharmacol; 2007 Nov; 50(5):470-9. PubMed ID: 18030055
[TBL] [Abstract][Full Text] [Related]
16. Influence of simultaneous inhibition of cyclooxygenase-2 and inducible nitric oxide synthase in experimental colitis in rats.
Dudhgaonkar SP; Tandan SK; Kumar D; Raviprakash V; Kataria M
Inflammopharmacology; 2007 Oct; 15(5):188-95. PubMed ID: 17943250
[TBL] [Abstract][Full Text] [Related]
17. Rofecoxib regulates the expression of genes related to the matrix metalloproteinase pathway in humans: implication for the adverse effects of cyclooxygenase-2 inhibitors.
Wang XM; Wu TX; Lee YS; Dionne RA
Clin Pharmacol Ther; 2006 Apr; 79(4):303-15. PubMed ID: 16580899
[TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of new water-soluble tetrazolide derivatives of celecoxib and rofecoxib as selective cyclooxygenase-2 (COX-2) inhibitors.
Navidpour L; Amini M; Shafaroodi H; Abdi K; Ghahremani MH; Dehpour AR; Shafiee A
Bioorg Med Chem Lett; 2006 Sep; 16(17):4483-7. PubMed ID: 16806914
[TBL] [Abstract][Full Text] [Related]
19. Combining paracetamol with a selective cyclooxygenase-2 inhibitor for acute pain relief after third molar surgery: a randomized, double-blind, placebo-controlled study.
Haglund B; von Bültzingslöwen I
Eur J Oral Sci; 2006 Aug; 114(4):293-301. PubMed ID: 16911100
[TBL] [Abstract][Full Text] [Related]
20. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
Rahme E; Nedjar H
Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]